{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:45:56Z","timestamp":1769755556757,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jns.2021.117530","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T23:14:46Z","timestamp":1622675686000},"page":"117530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"427","author":[{"given":"Alex","family":"Exuzides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sheinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2021.117530_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.jns.2021.117530_bb0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2021.117530_bb0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.jns.2021.117530_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-014-3066-3","article-title":"Neuromyelitis optica spectrum disorders associated with other autoimmune diseases","volume":"35","author":"Freitas","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"6","key":"10.1016\/j.jns.2021.117530_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11882-016-0619-4","article-title":"Common and rare manifestations of neuromyelitis optica spectrum disorder","volume":"16","author":"Rosales","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jns.2021.117530_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102425","article-title":"Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001\u20132015","volume":"45","author":"Fang","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.117530_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity."},{"key":"10.1016\/j.jns.2021.117530_bb0040","doi-asserted-by":"crossref","DOI":"10.4103\/sni.sni_224_18","article-title":"Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico","volume":"9","author":"Zarei","year":"2018","journal-title":"Surg. Neurol. Int."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2021.117530_bb0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"4","key":"10.1016\/j.jns.2021.117530_bb0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"9","key":"10.1016\/j.jns.2021.117530_bb0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","article-title":"Clinical characteristics, course and prognosis of relapsing Devic\u2019s Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2021.117530_bb0075","doi-asserted-by":"crossref","first-page":"101452","DOI":"10.1016\/j.msard.2019.101452","article-title":"Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases","volume":"37","author":"Wildner","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2021.117530_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"10.1016\/j.jns.2021.117530_bb0090","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1352458519868796","article-title":"MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity \u2013 yes","volume":"26","author":"Leite","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.jns.2021.117530_bb0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.jns.2021.117530_bb0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med. (Lond)."},{"key":"10.1016\/j.jns.2021.117530_bb0105","series-title":"IBM MarketScan Research Databases for Health Services Researchers","year":"2019"},{"issue":"3","key":"10.1016\/j.jns.2021.117530_bb0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-NMDA receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.117530_bb0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatrica."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12883-014-0162-7","article-title":"Neuromyelitis optica spectrum disorders without and with autoimmune diseases","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2021.117530_bb0125","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"issue":"4","key":"10.1016\/j.jns.2021.117530_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2021.117530_bb0135","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.msard.2020.102542","article-title":"Neuromyelitis optica spectrum disorder in China: quality of life and medical care experience","volume":"46","author":"Huang","year":"2020","journal-title":"Mult. Scler. Rel. Disord."},{"key":"10.1016\/j.jns.2021.117530_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2015.11.031","article-title":"Cognitive and psychiatric comorbidities in neuromyelitis optica","volume":"360","author":"Moore","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2021.117530_bb0145","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458511404917","article-title":"Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"17","author":"Kim","year":"2011","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2021.117530_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.jns.2021.117530_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.117530_bb0160","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"13","key":"10.1016\/j.jns.2021.117530_bb0165","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis: ACR RA treatment recommendations","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.jns.2021.117530_bb0175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jns.2021.117530_bb0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.jns.2021.117530_bb0185","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2021.117530_bb0190","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus \u2013 safety, preliminary efficacy, and impact on circulating plasma cells","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jns.2021.117530_bb0195","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"25","key":"10.1016\/j.jns.2021.117530_bb0200","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2021.117530_bb0205","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jns.2021.117530_bb0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract. Neurol."},{"issue":"10206","key":"10.1016\/j.jns.2021.117530_bb0215","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jns.2021.117530_bb0220","author":"US Food and Drug Administration"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:56:29Z","timestamp":1758383789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21002240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":44,"alternative-id":["S0022510X21002240"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117530","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117530"}}